Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Economic and Social Standing of Individuals in Iran Diagnosed with Multiple Sclerosis.
Ghadiri F, Sahraian MA, Ashtari F, Baghbanian SM, Majdi-Nasab N, Hatamian H, Faraji F, Bayati A, Sharifipour E, Jalali N, Mozhdehipanah H, Kamali H, Ayoubi S, Eskandarieh S, Naser Moghadasi A. Ghadiri F, et al. Among authors: faraji f. Arch Iran Med. 2023 Aug 1;26(8):413-418. doi: 10.34172/aim.2023.63. Arch Iran Med. 2023. PMID: 38301102 Free PMC article.
Prescription trends of disease-modifying treatments for multiple sclerosis in Iran over the past 30 years.
Ghadiri F, Sahraian MA, Baghbanian SM, Ashtari F, Razazian N, Majdinasab N, Poursadeghfard M, Hatamian H, Harirchian MH, Beladimoghadam N, Azimi A, Sharifipour E, Hosseini S, Bayati A, Kamali H, Hosseni Nejad Mir N, Faraji F, Mozhdehipanah H, Modara F, Navardi S, Heidari H, Ayoubi S, Naser Moghadasi A, Eskandarieh S. Ghadiri F, et al. Among authors: faraji f. Mult Scler Relat Disord. 2022 May;61:103777. doi: 10.1016/j.msard.2022.103777. Epub 2022 Mar 27. Mult Scler Relat Disord. 2022. PMID: 35390594
Safety and Effectiveness of Cinnomer® on Disease Characteristics, Depression, and Quality of Life of Patients with Multiple Sclerosis: A Phase IV, Post-marketing, Prospective, Multicenter Study.
Naser Moghadasi A, Ashtari F, Baghbanian SM, Shaygannejad V, Anjidani N, Ghadiri F, Sedighi B, Saeidi M, Amirifard H, Ayromlou H, Beladi Moghadam N, Ranjbar MB, Nazeri M, Niknam Z, Faraji F, Afsorde A, Sahraian MA. Naser Moghadasi A, et al. Among authors: faraji f. Arch Iran Med. 2023 Nov 1;26(11):647-653. doi: 10.34172/aim.2023.95. Arch Iran Med. 2023. PMID: 38310425 Free PMC article. Clinical Trial.
Time interval between the onset of symptoms and diagnosis of multiple sclerosis and the influential factors: A national registry-based study.
Khodaie F, Moghadasi AN, Hosseinnataj A, Baghbanian SM, Ashtari F, Razazian N, Poursadeghfard M, Majdi-Nasab N, Hatamian H, Hoseini S, Nahayati MA, Nabavi SM, Faraji F, Harirchian MH, Mir NHN, Moghadam NB, Sharifipour E, Bayati A, Kamali H, Mozhdehipanah H, Jalali N, Abotorabi-Zarchi M, Kamyari N, Nikbakht R, Azimi A, Navardi S, Heidari H, Sahraian MA, Eskandarieh S. Khodaie F, et al. Among authors: faraji f. Clin Neurol Neurosurg. 2024 Apr;239:108221. doi: 10.1016/j.clineuro.2024.108221. Epub 2024 Mar 2. Clin Neurol Neurosurg. 2024. PMID: 38447483
Multiple sclerosis and environmental risk factors: a case-control study in Iran.
Abbasi M, Nabavi SM, Fereshtehnejad SM, Jou NZ, Ansari I, Shayegannejad V, Mohammadianinejad SE, Farhoudi M, Noorian A, Razazian N, Abedini M, Faraji F. Abbasi M, et al. Among authors: faraji f. Neurol Sci. 2017 Nov;38(11):1941-1951. doi: 10.1007/s10072-017-3080-9. Epub 2017 Aug 10. Neurol Sci. 2017. PMID: 28799006
173 results